Translation of "contact à plasma " (French → English) :

plasma contactor unit [ PCU | plasma contactor ]

inductively coupled plasma-mass spectrometry | ICP-MS | ICP-mass spectrometry

inductively coupled plasma-mass spectrometer | ICP-MS | ICP-mass spectrometer

inductively coupled plasma-atomic emission spectrometry | ICP-AES | inductively coupled plasma-optical emission spectrometry | ICP-OES | ICP-atomic emission spectrometry | ICP-optical emission spectrometry

plasma gun [ plasma torch | plasma spray gun ]

multiple collector inductively coupled plasma mass spectrometer [ MC-ICP-MS | multiple collector ICP-MS | multicollector inductively coupled plasma mass spectrometer | multi-collector sector ICP-MS | multi-collector ICP-MS ]

Plasma propulsion

temperature compensated pressure switch

spring finger

FDHA Ordinance of 23 November 2005 on Articles intended for contact with Mucous Membranes, Skin and Hair and on Candles, Matches, Lighters and Joke and Novelty Items | Ordinance on Articles intended for Human Contact

(b) ensure that all surfaces intended to come into contact with blood or plasma are pyrogen free;

(Return tabled) Question No. 1340 Mr. Matthew Kellway: With regard to the issue of the proposed for-profit blood plasma clinics in Toronto and Hamilton, Ontario: (a) when was Health Canada approached by the operators of the proposed for-profit blood plasma clinics; (b) how many consultations took place between Health Canada and the operators of the proposed for-profit blood plasma clinics; (c) how many consultations took place between Health Canada and (i) Canadian Blood Services, (ii) the province of Ontario; (d) when did these consultations take place and if no consultations took place, how did Health Canada determine that consultat ...[+++]ions were not necessary; (e) when were the locations for the proposed clinics approved; (f) what process did the operators of the proposed for-profit blood plasma clinics follow to obtain approval for the location of the clinics; (g) what is Health Canada’s policy on the operation of for-profit blood plasma clinics in Canada; (h) what is Health Canada’s policy with regard to following the recommendations of the Royal Commission of Inquiry on the Blood System in Canada (“Krever report”); (i) what existing statutes, regulations, auditing processes, etc. are in place to ensure the safety of Canada’s blood supply; (j) with regard to ensuring the safety of Canada’s blood supply, what is the regulatory role of (i) Health Canada, (ii) the province, (iii) Canadian Blood Services; (k) what role does Canadian Blood Services play in the establishment or regulation of for-profit blood plasma clinics in Canada; (l) what does Health Canada’s auditing process for licensing for-profit blood plasma clinics in Canada involve; (m) what information is provided to Health Canada by the operators; (n) how often does Health Canada audit these clinics; and (o) what is the relationship between Health Canada and the U.S. Food and Drug Administration in ensuring the safety of blood plasma products purchased from the United States of America?

He said that in addition to maintaining contact with the Member States he had asked his Services to meet with representatives of the sectors involved in supplying blood and plasma products in order to assess the current situation.

The Commission has contacted in its enquiry a number of hospitals specialised in the area of plasma derivatives, and in particular those specialised in the treatment of haemophilia, since they constitute the main customers of Immuno and Baxter.